Clinical evaluation of recombinant human growth hormone combined with triptorelin in the treatment of idiopathic central precocious puberty in girls
CHEN Pingping
LIU Wei
SHAO Jingxian
Abstract：Objective To explore the clinical efficacy of recombinant human growth hormone combined with triptorelin in the treatment of idiopathic central precocious puberty(ICPP)in girls.Methods A total of 136 girls diag-nosed with ICPP who visited the Department of Pediatrics at Huai'an First People's Hospital from May 2022 to May 2024 were retrospectively selected and divided into the control group(n=66)and the observation group(n=70)based on treatment regimens.The control group received conventional intervention combined with triptorelin therapy,while the observation group received conventional intervention plus recombinant human growth hormone(rhGH)and triptorelin.The treatment course was 12 months for all patients.The clinical efficacy,levels of serum sex hormone(luteinizing hormone(LH),folli-cle stimulating hormone(FSH),and estradiol(E2)),developmental indicators(uterine volume,ovarian volume,and max-imum follicle diameter),bone age indicators(bone age index(BAI),bone age difference(BAD)),predicted adult height,and the incidence of adverse drug reactions during treatment were compared between the control group and the observation group.Results The total effective rate of the control group was 92.42%(61/66),slightly lower than that of the observa-tion group(97.14%(68/70)),and the difference was not statistically significant(χ2=1.549,P=0.213).After treatment,the levels of serum LH,FSH and E2 in the control group and the observation group((4.13±1.04)IU/L,(3.24±0.93)IU/L,and(15.38±4.45)pg/mL;(2.46±0.69)IU/L,(1.75±0.49)IU/L,and(10.56±3.06)pg/mL,respectively)were all lower than those before treatment,and the above indicators in the observation group were significant lower than those in the control group(t=11.094,11.783,7.396,all P<0.05).After treatment,the uterine volume,ovarian volume and follicle diameter in the con-trol group and the observation group((3.31±0.27)mL,(1.50±0.23)mL,and(4.34±0.40)mm;(2.18±0.20)mL,(1.13±0.14)mL,and(3.27±0.29)mm,respectively)were all lower than those before treatment,and these indicators in the observation group were significant lower than those in the control group(t=27.842,11.405,17.935,all P<0.05).After treatment,the BAI and BAD of the control group and the observation group((1.63±0.26)and(0.65±0.15)years;(1.25±0.24)and(0.43±0.09)years,re-spectively)were both lower than those before treatment,and these indicators in the observation group were significant lower than those in the control group(t=8.863,10.440,both P<0.05).After treatment,the predicted lifetime heights of the control group and the observation group((154.38±4.11)cm and(159.12±4.45)cm,respectively)were higher than those before treatment,and these indicators in the observation group were significant higher than those in the control group(t=6.442,P<0.05).The incidence of adverse reactions during treatment in the control group and the observation group was 13.64%(9/66)and 12.86%(9/70),respec-tively,with no statistically significant difference(χ2=0.018,P=0.893).Conclusion The combination of recombinant human growth hormone and triptorelin treatment can synergistically inhibit gonadal development in girls with ICPP,enhance clinical efficacy,and delay bone age progression,demonstrating good safety.
Keywords：girlsidiopathic central precocious pubertyrecombinant human growth hormonetriptorelinclinical effi-cacybone age
Publication Date：2025-11-25
Online Publishing Date：2025-12-04(First online date of this platform, not the publication date of the document)
Pages：5( 1381-1385 )